A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Gross, Mitchell ^a   Higano, Celestia ^b   Pantuck, Allan ^c   Castellanos, Olga ^a   Green, Erica ^a   Nguyen, Koo ^a   Agus, David B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; ERLOTINIB; FLUTAMIDE; HEMOGLOBIN; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; TAXOID;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE METASTASIS; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; EYE IRRITATION; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; KERATITIS; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; ADENOCARCINOMA; METASTASIS; MORTALITY; PROSTATE TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUINAZOLINES; SURVIVAL RATE; TAXOIDS;

EID: 34547851605     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-142     Document Type: Article

References (22)

1. Jemal A Siegel R Ward E Murray T Xu J Smigal C Thun MJ Cancer statistics, 2006 CA Cancer J Clin 2006 56 2 106-130 16514137
2. Tannock IF Osoba D Stockler MR Ernst DS Neville AJ Moore MJ Armitage GR Wilson JJ Venner PM Coppin CM Murphy KC Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points J Clin Oncol 1996 14 6 1756-1764 8656243
3. Kantoff PW Halabi S Conaway M Picus J Kirshner J Hars V Trump D Winer EP Vogelzang NJ Hydrocortisone with or without mitoxantrone in men with hormone- refractory prostate cancer: Results of the cancer and leukemia group B 9182 study J Clin Oncol 1999 17 8 2506-2513 10561316
4. Tannock IF de Wit R Berry WR Horti J Pluzanska A Chi KN Oudard S Theodore C James ND Turesson I Rosenthal MA Eisenberger MA Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 2004 351 15 1502-1512 10.1056/NEJMoa040720 15470213
5. Petrylak DP Tangen CM Hussain MH Lara PN Jr. Jones JA Taplin ME Burch PA Berry D Moinpour C Kohli M Benson MC Small EJ Raghavan D Crawford ED Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 2004 351 15 1513-1520 10.1056/NEJMoa041318 15470214
6. Agus DB Akita RW Fox WD Lofgren JA Higgins B Maiese K Scher HI Sliwkowski MX A potential role for activated HER-2 in prostate cancer Semin Oncol 2000 27 6 Suppl 11 76-83; discussion 92-100. 11236032
7. Gross ME Jo S Agus DB Update on HER-Kinase-Directed Therapy in Prostate Cancer Clin Adv Hematol Oncol 2004 2 1 53-64 16163160
8. Arteaga CL The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia J Clin Oncol 2001 19 18 Suppl 32S-40S 11560969
9. Craft N Shostak Y Carey M Sawyers CL A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase Nat Med 1999 5 3 280-285 10.1038/6495 10086382
10. Signoretti S Montironi R Manola J Altimari A Tam C Bubley G Balk S Thomas G Kaplan I Hlatky L Hahnfeldt P Kantoff P Loda M Her-2-neu expression and progression toward androgen independence in human prostate cancer J Natl Cancer Inst 2000 92 23 1918-1925 10.1093/jnci/ 92.23.1918 11106683
11. Moore MJ Goldstein D Hamm J Figer A Hecht J Gallinger S Au H Ding K Christy-Bittel J W. P Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] Proc Am Soc Clin Oncol 2005 23 16S Abstract 1
12. Shepherd FA Rodrigues Pereira J Ciuleanu T Tan EH Hirsh V Thongprasert S Campos D Maoleekoonpiroj S Smylie M Martins R van Kooten M Dediu M Findlay B Tu D Johnston D Bezjak A Clark G Santabarbara P Seymour L Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 2005 353 2 123-132 10.1056/NEJMoa050753 16014882
13. Forouzesh B Hidalgo M Takimoto C de Bono JS Forero L al. E Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel Proc Am Soc Clin Oncol 2002 21 Abstract 81
14. Petrylak DP Tangen C Hussain M Lara PN Jones J Talpin ME Burch P Greene G Small E Crawford ED SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA). Proc ASCO 2004 23 2 (abstract 3)
15. Chen H Cantor A Meyer J Beth Corcoran M Grendys E Cavanaugh D Antonek S Camarata A Haley W Balducci L Extermann M Can older cancer patients tolerate chemotherapy? A prospective pilot study Cancer 2003 97 4 1107-1114 10.1002/cncr.11110 12569613
16. Therasse P Arbuck SG Eisenhauer EA Wanders J Kaplan RS Rubinstein L Verweij J Van Glabbeke M van Oosterom AT Christian MC Gwyther SG New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000 92 3 205-216 10.1093/jnci/92.3.205 10655437
17. Bubley GJ Carducci M Dahut W Dawson N Daliani D Eisenberger M Figg WD Freidlin B Halabi S Hudes G Hussain M Kaplan R Myers C Oh W Petrylak DP Reed E Roth B Sartor O Scher H Simons J Sinibaldi V Small EJ Smith MR Trump DL Wilding G Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 1999 17 11 3461-3467 10550143
18. Giaccone G Herbst RS Manegold C Scagliotti G Rosell R Miller V Natale RB Schiller JH Von Pawel J Pluzanska A Gatzemeier U Grous J Ochs JS Averbuch SD Wolf MK Rennie P Fandi A Johnson DH Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1 J Clin Oncol 2004 22 5 777-784 10.1200/ JCO.2004.08.001 14990632
19. Herbst RS Giaccone G Schiller JH Natale RB Miller V Manegold C Scagliotti G Rosell R Oliff I Reeves JA Wolf MK Krebs AD Averbuch SD Ochs JS Grous J Fandi A Johnson DH Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 J Clin Oncol 2004 22 5 785-794 10.1200/ JCO.2004.07.215 14990633
20. Herbst RS Prager D Hermann R Fehrenbacher L Johnson BE Sandler A Kris MG Tran HT Klein P Li X Ramies D Johnson DH Miller VA TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 2005 23 25 5892-5899 10.1200/JCO.2005.02.840 16043829
21. Gatzemeier U Pluzanska A Szczesna A Kaukel E Roubec J Brennscheidt U De Rosa F Mueller B Von Pawel J Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004 22 14S Abstract 7010
22. Malik SN Siu LL Rowinsky EK deGraffenried L Hammond LA Rizzo J Bacus S Brattain MG Kreisberg JI Hidalgo M Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients Clin Cancer Res 2003 9 7 2478-2486 12855621